NEW YORK (360Dx) – SQI Diagnostics and Microdrop on Thursday announced an agreement to sell SQI's celiac and wheat allergy, and rheumatoid arthritis tests to the directly to consumers.
Microdrop will license the rights to the two SQI microarray-based tests. The rights are subject to performance obligations by both parties, including a minimum number of kits to be purchased by Microdrop, they said.
Microdrop will also purchase two sqidlite testing systems upon the signing of the agreement. The benchtop system can process one plate per run with a time-to-result of three hours, according to SQI's website. The CE-marked platform quantitates proteins, isotypes, and subclasses and has sensitivity down to the picogram per milliliter range with a coefficient of variation as low as 10 percent, SQI said.
Financial and other terms of the deal were not disclosed.